Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy pens are stored in the fridge, but you do not need to bring the pen to room temperature before injecting. The manufacturer's guidance and the NHS semaglutide medicines page confirm that Wegovy can be injected straight from the fridge if needed — though many people find a cold pen slightly less comfortable at the injection site. This is a practical preference, not a clinical requirement. These pens contain semaglutide, a prescription-only medicine prescribed only after a clinical assessment confirms it is suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes. The Wegovy pre-filled pen is designed to be used from refrigerated storage and does not require warming before use. This distinguishes it from some older injectable medicines where room-temperature warming was mandatory. If you have just arrived home to your plain, tracked DPD delivery, taken the pen from the cool-pack and want to use it that day, you can do so immediately.
That said, a pen that has been sitting at 2°C will feel noticeably cooler against the skin, and some people report a brief stinging sensation when injecting cold liquid into the abdomen, thigh or upper arm. This is not harmful, but it is real. Letting the pen sit passively on a clean surface for around 20 to 30 minutes before use tends to reduce that sensation for most people. The key word is passively: no hot water bath, no microwave, no radiator. These methods heat unevenly and can degrade the medicine.
For everything relating to how long Wegovy can safely stay at room temperature, the authoritative source is your pen's Patient Information Leaflet, which sets out the precise time window for your specific product version. That figure takes precedence over any general statement you may read online.
There is no clinical evidence that injecting a cool pen produces a different pharmacological effect to injecting one at ambient temperature. The active ingredient, semaglutide, is absorbed subcutaneously regardless of whether the liquid is 4°C or 20°C when it enters the tissue. So warming the pen is entirely about your comfort during the injection, not about efficacy.
What does affect the medicine is sustained exposure to temperatures outside the permitted range: heat above 30°C, freezing, or direct sunlight. A pen that has been left in a car on a warm day or accidentally placed in the freezer compartment should not be used. If you are unsure whether a pen has been stored correctly, the guidance on Wegovy expiry and storage integrity covers what to look for and when to contact your pharmacy.
More detail on safe temperature requirements for storing Wegovy is set out in a dedicated page if you want to go deeper on the refrigeration rules.
Passive warming at room temperature is the only appropriate method. Remove the pen from the fridge, place it on a clean, dry surface away from heat sources or sunlight, and wait. That is the entirety of the guidance. Twenty to thirty minutes is the range most commonly cited by Novo Nordisk in patient-facing materials, but your specific leaflet sets the exact permitted window, and once that window closes, the pen should be used or discarded, not returned to cold storage.
A question our prescribers hear fairly often is whether holding the pen in your hand for a few minutes counts as warming. Gentle hand-warming is unlikely to cause any harm, but it is not controlled enough to rely on, and it is not what the leaflet describes. Sticking to passive room-temperature rest keeps things straightforward and consistent.
If side effects after injecting (such as nausea, fatigue or dizziness) are a concern for you, those are covered separately on the page about fatigue and post-injection symptoms. Temperature of the pen is not linked to those effects.
Semaglutide is used in more than one product. Ozempic contains semaglutide but is licensed for type 2 diabetes, not for weight management, they are different products with different licensed uses, even though the active molecule is the same. The storage and pre-injection temperature principles are broadly similar across semaglutide pens, but you should always follow the specific leaflet for the product you have been prescribed, as pen mechanisms, dose volumes and approved storage windows can differ between products and formulations.
Wegovy itself now comes in more than one pen format following the MHRA's approval of the higher 7.2mg single-dose pen in April 2026. Novo Nordisk's leaflet for each format sets its own permitted out-of-fridge window. If you are unsure which format you have or what rules apply to it, your prescriber is the right person to ask, and you can also check the guidance on whether semaglutide can be kept at room temperature for a broader look at how the rules work across formats. For a full overview of the Wegovy treatment itself, the Wegovy treatment page covers eligibility, how it works and how to access it through a regulated UK pharmacy.
If you are considering starting Wegovy and want a clinical assessment from a GPhC-registered prescriber, speak to our prescribers through a free consultation, reviewed the same day, with no waiting list.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.